Explore

USA TodayUSA Today
TrumpRx claims the world's lowest drug prices. A new report raises doubts

TrumpRx claims the world's lowest drug prices. A new report raises doubts

KFF's analysis of 32 brand name drugs found TrumpRx's claim of big discounts compared to peer nations delivered mixed results.
Rapid ReadRapid Read
Doctors Warn of Vision Loss Risk Linked to Popular Weight-Loss Drugs

Doctors Warn of Vision Loss Risk Linked to Popular Weight-Loss Drugs

Multiple lawsuits have been filed in the past year concerning a condition called non-arteritic anterior ischemic optic neuropathy (NAION), which causes rapid-onset vision changes and potential blindness, reportedly linked to popular weight-loss drugs. Dr. Elizabeth Steele of the UAB Department of Optometry explains that NAION involves a blood pressure issue at the optic nerve, a structure vital for connecting the eye to the brain and requiring proper blood flow and pressure. This condition typically affects aging adults with pre-existing conditions such as high blood pressure, obesity, diabetes, and high cholesterol, which are often the same patient demographics prescribed these weight-loss medications. Additionally, GLP-1 drugs, particularly semaglutide, are being investigated for a second potential link to vision loss. For patients with severe diabetes, rapid blood sugar control and significant weight loss in the initial months of taking the drug can compromise the vascular system in the retina, increasi...
TheStreetTheStreet
Medicare just handed Eli Lilly a massive weight-loss win

Medicare just handed Eli Lilly a massive weight-loss win

As Medicare Bridge participation surges, Novo Nordisk's share of those new patients is drawing attention.
TheStreetTheStreet
91-year-old investor sees healthcare titan doubling in 3 years

91-year-old investor sees healthcare titan doubling in 3 years

The billionaire Home Depot co-founder has held the stock since 1977. Here's where he thinks it's going.
EATEREATER
Unapologetic Foods Closes its Union Square Kebab Restaurant

Unapologetic Foods Closes its Union Square Kebab Restaurant

Plus, a Brooklyn ice cream shop  — and more restaurant shutters
TrendlineTrendline
Novo Nordisk Licenses Nanexa's PharmaShell Technology for Long-Acting GLP-1 Treatments

Novo Nordisk Licenses Nanexa's PharmaShell Technology for Long-Acting GLP-1 Treatments

Novo Nordisk Licenses Nanexa's PharmaShell Technology for Long-Acting GLP-1 Treatments
Discover dailyDiscover daily
Illuminate Debuted at No. 1 in Both the U.S. and Canada

Illuminate Debuted at No. 1 in Both the U.S. and Canada

Shawn Mendes, the Canadian singer-songwriter, released his second studio album, "Illuminate," on September 23, 2016, through Island Records. This a...
Rapid ReadRapid Read
U.S. Lawsuits Allege Vision Loss from GLP-1 Drugs Ozempic and Wegovy

U.S. Lawsuits Allege Vision Loss from GLP-1 Drugs Ozempic and Wegovy

A growing number of lawsuits in the U.S. are alleging that GLP-1 class drugs, including Ozempic and Wegovy, are causing non-arteritic anterior ischaemic optic neuropathy (NAION), a condition leading to sudden, potentially irreversible vision loss. Over 90 lawsuits have been filed against Novo Nordisk in New Jersey, with additional cases in federal court in Pennsylvania, targeting manufacturers like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound). Plaintiffs claim that these manufacturers failed to adequately warn patients about the risk of NAION. NAION, often described as an 'eye stroke,' results from reduced blood supply to the optic nerve and typically affects one eye. While the U.S. Food and Drug Administration (FDA) is investigating the possible link, it has not yet added a specific NAION warning to GLP-1 drug labels. Manufacturers dispute these allegations, with Novo Nordisk stating its research found no increased risk.
TrendlineTrendline
Novo Nordisk Explores Hair Loss Market for Diversification Beyond GLP-1 Drugs

Novo Nordisk Explores Hair Loss Market for Diversification Beyond GLP-1 Drugs

Novo Nordisk Explores Hair Loss Market for Diversification Beyond GLP-1 Drugs
Rapid ReadRapid Read
GLP-1 Drugs Prescribed Off-Label to Children as Young as 8 for Obesity Treatment in U.S.

GLP-1 Drugs Prescribed Off-Label to Children as Young as 8 for Obesity Treatment in U.S.

A growing number of children in the U.S., some as young as 8, are being prescribed GLP-1 weight-loss drugs off-label to treat obesity. A study led by Babak Orandi at New York University found that 9.3% of children aged 8 to 11 with obesity but without diabetes are receiving these medications, a significant increase from 0.03% in 2019. While GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) are only approved for individuals aged 12 and older in the U.S., UK, and Australia, off-label prescriptions for younger children are occurring in line with guidance from the American Academy of Pediatrics. These prescriptions are more common in children with severe obesity or related complications such as pre-diabetes, sleep apnea, high blood pressure, or high cholesterol, and tend to be among wealthier families due to the high cost of the medication.
TheStreetTheStreet
Novo Nordisk CEO opens the door to major move for U.S. investors

Novo Nordisk CEO opens the door to major move for U.S. investors

The U.S. now accounts for more than half of Novo Nordisk’s revenue.
ReutersReuters
Novo Nordisk open to direct New York listing, CEO Doustdar tells FT

Novo Nordisk open to direct New York listing, CEO Doustdar tells FT

Sept 23 (Reuters) - Novo Nordisk is open to considering a direct New York Stock Exchange listing, replacing the American depositary receipts through which US investors currently trade its shares, CEO Mike Doustdar told the Financial Times in an interview published on Wednesday.